Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Psychiatric Adverse Events: Navigating a New Drug Safety Landmine

This article was originally published in RPM Report

Executive Summary

Psychiatric drug safety isn't just about antidepressants any more. An increased risk of depression and suicidality is killing new drug prospects and has threatened multi-billion dollar franchises. FDA aims to help by injecting some clarity and predictability into the process. Now It's up to sponsors to take advantage of ithe FDA's initiatives.

You may also be interested in...



The Billion Dollar REMS: Xenazine and the Value of Facing Regulatory Realities

Prestwick's Huntington's chorea therapy won FDA approval in August, triggering a flurry of deals valued at over $1 billion. Not bad for a 50-year-old drug expected to treat no more than 5,000 patients-and a powerful case study in how embracing the new regulatory realities can pay off.

The Billion Dollar REMS: Xenazine and the Value of Facing Regulatory Realities

Prestwick's Huntington's chorea therapy won FDA approval in August, triggering a flurry of deals valued at over $1 billion. Not bad for a 50-year-old drug expected to treat no more than 5,000 patients-and a powerful case study in how embracing the new regulatory realities can pay off.

The Impact of FDAAA On Drug Approvals: Setting the Baseline

An analysis of the first six months of the new era in drug regulation shows that FDA is enthusiastically and creatively applying its new drug safety tools. Biopharma companies will be watching carefully to see how the metrics of the FDAAA era move over time.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS080430

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel